Winner Medical(300888) 华福证券·2025-05-29 09:53Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [4][9]. Core Views - The company is gradually returning to normal operations, with a strong confidence signal from the equity incentive plan launched in 2024, and an upward brand trajectory expected in 2025 [2][4]. - The company has established itself as a leading player in the medical and consumer health sectors, with significant growth potential in both segments [2][4]. Summary by Sections Company Overview - The company, established in 1991, has become a leading brand in the medical and consumer health sectors in China, with two main brands: "Winner" and "Purcotton" [2][16]. - The business covers various fields including wound care, infection protection, personal care, family care, maternal and infant care, and home textiles [2][16]. Consumer Products Segment - The "Purcotton" brand leverages its strong medical background to create a comprehensive range of cotton-based products, targeting family consumption across various scenarios [3][44]. - Key products include cotton soft towels and sanitary napkins, with the former showing a market capacity of over 100 billion and a growth rate of 38.6% in Q1 2025 [3][44]. - The sanitary napkin market is valued at over 100 billion, with a remarkable growth of 73.5% in Q1 2025, driven by quality improvements and effective marketing strategies [3][57]. Medical Supplies Segment - The medical supplies segment has shown resilience, with a 12% growth in internal revenue since the second half of 2024, excluding GRI [3][4]. - In Q1 2025, the medical supplies segment's exports grew by 84.1%, indicating strong international demand, particularly in Europe and Japan [3][4]. - The company is enhancing its local production and operational capabilities in the U.S. following the completion of the GRI acquisition, which is expected to reduce risks in expanding overseas [3][4]. Financial Forecast and Investment Recommendations - The company is projected to achieve net profits of 10.4 billion, 12.4 billion, and 14.7 billion from 2025 to 2027, with year-on-year growth rates of 50.1%, 19.0%, and 18.8% respectively [4][11]. - The current stock price corresponds to a PE ratio of 27X for 2025, slightly below the average of comparable companies, indicating a favorable investment opportunity [4][11].